Compare AROW & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROW | VOR |
|---|---|---|
| Founded | 1851 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 755.7M |
| IPO Year | 1995 | 2021 |
| Metric | AROW | VOR |
|---|---|---|
| Price | $36.41 | $16.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $28.00 | ★ $45.33 |
| AVG Volume (30 Days) | 87.5K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.36 | N/A |
| Revenue Next Year | $18.26 | N/A |
| P/E Ratio | $13.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.34 | $0.13 |
| 52 Week High | $36.55 | $49.95 |
| Indicator | AROW | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 75.06 | 55.16 |
| Support Level | $31.14 | $11.38 |
| Resistance Level | $36.44 | $16.88 |
| Average True Range (ATR) | 0.74 | 1.63 |
| MACD | 0.35 | 0.05 |
| Stochastic Oscillator | 95.91 | 50.81 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.